Zami Aberman
2016
In 2016, Zami Aberman earned a total compensation of $709.6K as Co, CEO at Pluristem Therapeutics, a 30% decrease compared to previous year.
Compensation breakdown
| Salary | $519,050 |
|---|---|
| Stock Awards | $169,500 |
| Other | $21,074 |
| Total | $709,624 |
Aberman received $519.1K in salary, accounting for 73% of the total pay in 2016.
Aberman also received $169.5K in stock awards and $21.1K in other compensation.
Rankings
In 2016, Zami Aberman's compensation ranked 9,815th out of 14,075 executives tracked by ExecPay. In other words, Aberman earned more than 30.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,815 out of 14,075 | 30th |
Division Manufacturing | 3,794 out of 5,489 | 31st |
Major group Chemicals And Allied Products | 1,326 out of 1,895 | 30th |
Industry group Drugs | 1,055 out of 1,538 | 31st |
Industry Biological Products, Except Diagnostic Substances | 186 out of 279 | 33rd |
Source: SEC filing on April 3, 2018.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2016.
2016
Yaky Yanay
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019